Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Ortiz Lituma, Adriana Mayumi"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Item
    Tecnologías de secuenciación de nueva generación en el diagnóstico temprano de cáncer de mama hereditario. Revisión sistemática según las directrices PRISMA
    (Universidad de Cuenca, 2025-05-12) Analuisa Carchi, Katleen Dayanara; Ortiz Lituma, Adriana Mayumi; Jaramillo Oyervide, Julio Alfredo
    Introduction: breast cancer is the most common among women globally, with 5-10% being hereditary and primarily caused by BCR1/2 mutations (Breast Cancer Gene1/2). Variants and mutations in other genes predispose to this cancer and can be detected through Next-Generation Sequencing (NGS) technologies (1,3). This Systematic Review aims to determine the benefits of NGS compared to traditional genetic tests. Objective: to synthesize available scientific evidence on Next-Generation Sequencing technologies in the early diagnosis of hereditary breast cancer, applying the PRISMA 2020 methodology. Method: an observational retrospective study of Systematic Literature Review using digital databases: Scopus, PubMed, Science Direct, BVS, and Scielo for information retrieval. The data collection tool is the Ad Hoc-created data extraction matrix in Excel 2016. Quality and risk of bias were evaluated using the Sackett and Robis scales, respectively. Results: 9 articles analyzed suggest that NGS techniques enable the detection of pathogenic mutations different from BRCA1/2 genes and the identification of variants of uncertain significance (VUS). The importance of applying multigene panels in patients with family history and negative results for traditional tests is emphasized. Conclusions: NGS allows the detection of VUS and genetic mutations different from BRCA1/2 in women with hereditary breast cancer. Multigene tests are replacing traditional sequencing methods.

DSpace software copyright © 2002-2025 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback